Search results
The Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Have Been Trimming Their Sales Forecasts
Simply Wall St. via Yahoo Finance· 2 years agoToday is shaping up negative for Clovis Oncology, Inc. (NASDAQ:CLVS) shareholders, with the analysts...
Why Clovis Oncology Zoomed 30% Higher Today
Motley Fool· 2 years agoCancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a...
Clovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 2 years agoClovis Oncology (NASDAQ:CLVS) Third Quarter 2022 ResultsKey Financial Results Revenue: US$30.7m...
Cancer Focused Clovis Oncology Files For Bankruptcy
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets...
Clovis, Isotopia Ink Clinical Supply Pact For Lutetium-177 Used In Its Targeted Cancer Radiation...
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd signed a clinical supply...
Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) posted a Q3 EPS loss of $(0.39), up from $(0.56) a year ago, on...
Clovis Oncology's Rubraca Hits Primary Goal In Prostate Cancer Settings
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) announced topline data from the Phase 3 TRITON3 trial,...
Clovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line...
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) announced results from a subgroup analysis from the Phase 3...
Why Clovis Oncology Stock Is Crushing It Today
Motley Fool· 2 years agoShares of Clovis Oncology (NASDAQ: CLVS) were skyrocketing 41.9% higher at 11:12 a.m. ET on Friday. The huge gain came after the company reported the voting results on three proposals following ...
Why Clovis Oncology Shares Jumped 158.9% in June
Motley Fool· 2 years agoClovis Oncology (NASDAQ: CLVS), a biopharmaceutical company that specializes in solid-tumor therapies, saw its shares skyrocket 158.9% in June, according to data from S&P Global Intelligence ...
